A recently published study explores the possible benefits to discontinuing an alpha-1 blocker after receiving combination therapy with a 5-alpha reductase inhibitor for the treatment of benign prostatic hyperplasia (BPH). In more symptomatic patients, or patients with confirmed, enlarged prostates, it is recommended to use both medication classes (alpha-1 blocker and 5-alpha reductase inhibitor) to minimize symptoms by relaxing the prostatic smooth muscle and reducing the size of the prostate – producing a potentially synergistic effect. This study found that withdrawal of alpha 1-blockers after a year of combination therapy did not worsen urinary symptoms, QOL, and voiding or storage function. This provides evidence that combination therapy may not be needed indefinitely for all patients.
Guest Authors: Erica Crannage, PharmD and Stephanie Crist, PharmD
Music by Good Talk
LDL Limbo: How Low is Too Low?
Top Ten Things Every Clinician Should Know About the 2018 Antithrombotic Therapy Atrial Fibrillation Guidelines
Maybe Old is Gold? Newer Insulins Might Not Be Better – Just More Expensive
Using Controllers PRN for Mild Persistent Asthma – An Oxymoron?
The ZOE Trials – The Herpes Zoster Recombinant Subunit Vaccine — It’s Time to Upgrade!
Are You REAL-ly Paying Attention? The Importance of Attention Controls
Is it Time to “Step Up” Rescue Treatment for Asthma to Prevent Exacerbations?
Stop the Shots: Edoxaban vs Dalteparin in Cancer-Associated VTE Treatment
Hypertension – Time for Patients to Control the Wheel
Cutting Down HIV Treatment to a 2-Drug Regimen
Strategies for Managing Hypertension: Is the Paradigm Shifting?
Don’t Kid Yourself: Broad- versus Narrow-Spectrum Antibiotics in Children
Using Sotagliflozin In Tandem with Insulin: Weighing the Benefits in Type 1 Diabetes
Treating Opioid Use Disorder - X:BOT Offers a Pragmatic Approach
Can We KEEP Perimenopausal Women Sexually Satisfied?
ARCH Study: Is Romosozumab better than Alendronate for the Fracture-Prone?
SPRINTing towards lower BP goals : A re-analysis of the ACCORD-BP trial
Therapy for Early-Stage COPD: What is the GOLDen Regimen?
Inflammatory Statements about Cardiovascular Risk Reduction: The CANTOS Trial
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive